CCL2 and colorectal cancer: During bevacizumab treatment of colorectal cancer patients with positive expression of ETV5, the secretion of CCL2 induced by ETV5 resulted in persistent angiogenesis, indicating that CCL2 plays a critical role in bevacizumab resistance.